Every 8-K that ZOMEDICA CORP (ZOMDF) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ZOMDF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZOMDF filings page.
Zomedica reported record second-quarter 2026 revenue of $9.5 million, up 37% from $7.0 million a year earlier, marking its 22nd consecutive quarter of year-over-year revenue growth. Revenue for the first half of 2026 reached $18.3 million, a 36% increase. Growth was broad-based, led by Diagnostics revenue of $1.4 million (up 77%), Therapeutic Devices revenue of $6.8 million (up 9%), and Development Services revenue of $1.4 million in the quarter.
By product category, consumables generated $6.6 million in Q2 revenue (up 26%), capital sales were $1.9 million (up 11%), and engineering services contributed $1.0 million. Gross margin was 64% in the quarter and 63% year-to-date. Operating expenses fell 20% to $10.1 million, with double-digit declines across research and development, selling and marketing, and general and administrative costs.
Net loss narrowed to $3.8 million from $7.4 million, and Adjusted Non-GAAP EBITDA loss improved to $2.3 million from $5.5 million. For the first half, net loss was $8.3 million, significantly lower than $71.2 million in 2025, which included large impairment charges. Cash burn decreased 38% to $3.4 million, the lowest non-year-end level on record, and liquidity stood at $44.1 million in cash, cash equivalents, and available-for-sale securities as of June 30, 2026.
Zomedica Corp. reported the results of its June 10, 2026 annual shareholder meeting. Shareholders elected eight directors to one-year terms and ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ended December 31, 2026.
Shareholders approved an amendment to the company’s By-Laws regarding quorum requirements for adjourned shareholder meetings, with 123,410,315 votes for and 105,771,772 against. However, the non-binding advisory vote on executive compensation failed, with 99,891,977 votes for and 129,290,109 against, while 200,401,613 were broker non-votes.
Zomedica Corp. reported record first quarter 2026 revenue of $8.8 million, up 35% from $6.5 million a year earlier. Growth was driven by 73% higher Diagnostics sales, 22% growth in consumables, steady Therapeutic Device revenue at $5.8 million, and contributions from its Development Services segment.
Gross margin was 62%, while operating expenses excluding prior-year impairments fell 21% to $10.4 million. Net loss narrowed sharply to $4.5 million from $63.8 million, and Adjusted Non-GAAP EBITDA loss improved to $2.4 million from $5.7 million. Cash, cash equivalents, and available-for-sale securities totaled $47.5 million, with quarterly cash burn of $5.7 million, down 15% year over year.
Zomedica reported record 2025 results, with full-year revenue rising 17% to $32.0 million and fourth quarter revenue up 33% to $10.5 million. Growth was led by its PulseVet and Assisi therapeutic devices, expanding TRUFORMA diagnostics, and a new Development Services segment that generated $3.1 million.
Gross margin remained strong at 68% for the year and reached 69% in the fourth quarter. Adjusted operating expenses fell 7% to $50.2 million, helping reduce cash burn to $18.1 million for 2025, including just $1.1 million in the fourth quarter. Liquidity was $53.3 million as of December 31, 2025.
However, a non-cash impairment charge of $55.8 million, driven by lower market capitalization, pushed net loss to $81.9 million. Even excluding non-recurring and non-cash items, Adjusted Non-GAAP EBITDA remained a loss of $17.1 million, though this improved from a $20.2 million loss in 2024.
Zomedica Corp. furnished a Form 8-K stating it issued a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and is incorporated by reference. The company notes this information is being furnished and is not deemed “filed” under Section 18 of the Exchange Act. The filing lists Zomedica’s common shares trading as ZOMDF on the OTCQB and is dated November 4, 2025.